CRNX
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Crinetics Pharmaceuticals Inc (CRNX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Value (D+). The rating has held at C for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | D+ (1.6) | C (2.2) | C+ (2.8) | C+ (2.5) | C+ (2.6) | C (2.3) |
| 2026-11-04 | D+ (1.6) | C (2.2) | C+ (2.8) | C+ (2.5) | C+ (2.7) | C (2.3) |
| 2026-10-28 | D+ (1.7) | C- (2.1) | C+ (2.8) | C+ (2.5) | C+ (2.7) | C (2.4) |
| 2026-10-21 | D+ (1.8) | C- (2.1) | C+ (2.8) | C+ (2.5) | F (0.0) | D+ (1.8) |
| 2026-10-14 | D+ (1.7) | C- (2.1) | C+ (2.8) | C+ (2.5) | F (0.0) | D+ (1.8) |